AbbVie's Qulipta cleared for migraine prevention, setting up...

AbbVie has added a third drug to its arsenal in the crowded migraine market, getting FDA approval for Qulipta – its once-daily oral preventive therapy for episodic migraines.

Novartis’ Aimovig tops topiramate in migraine face-off

Novartis’ injectable migraine prevention antibody Aimovig has been shown to be more effective than topiramate – a go-to oral therapy for people with chronic migraine – in a head-to-head tri

After rejecting Novartis’ Aimovig for migraine, NICE backs T...

CHMP turns down Lilly’s Emgality for cluster headache

After rejection, NICE agrees to look again at migraine drug ...

Allergan builds case for migraine drug ubrogepant as FDA ver...